Scientists reprogram Patients' own cells to hunt deadly lung cancer
NCT ID NCT07509034
Summary
This is an early safety study testing a new cell therapy for people with a very aggressive form of lung cancer (small cell) or a similar rare cancer that has returned or not responded to standard treatments. Researchers will collect a patient's own immune cells, modify them in a lab to recognize a specific protein on cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose and see if this approach can help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.